

Raymond F Schinazi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5596527/publications.pdf>

Version: 2024-02-01

319
papers

13,533
citations

22153

59
h-index

31849

101
g-index

336
all docs

336
docs citations

336
times ranked

14401
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 74, 95-104.	5.8	31
2	GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition. <i>Viruses</i> , 2022, 14, 132.	3.3	10
3	Elimination of Aicardiâ€™s syndrome protein SAMHD1 activates cellular innate immunity and suppresses SARS-CoV-2 replication. <i>Journal of Biological Chemistry</i> , 2022, 298, 101635.	3.4	9
4	Inactivation of SARS-CoV-2 and COVID-19 Patient Samples for Contemporary Immunology and Metabolomics Studies. <i>ImmunoHorizons</i> , 2022, 6, 144-155.	1.8	5
5	Assessment of the Abbott BinaxNOW SARS-CoV-2 rapid antigen test against viral variants of concern. <i>IScience</i> , 2022, 25, 103968.	4.1	14
6	The Mechanism of Action of Hepatitis B Virus Capsid Assembly Modulators Can Be Predicted from Binding to Early Assembly Intermediates. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4854-4864.	6.4	8
7	<i>In silico</i> design of a novel nucleotide antiviral agent by free energy perturbation. <i>Chemical Biology and Drug Design</i> , 2022, , .	3.2	0
8	Diastereoselective Synthesis of 2â€™-Dihalopyrimidine Ribonucleoside Inhibitors of Hepatitis C Virus Replication. <i>ACS Omega</i> , 2022, 7, 1452-1461.	3.5	1
9	The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675.	1.0	4
10	Identification of Botanical Viral Entry Inhibitors for SARSâ€CoVâ€2. <i>FASEB Journal</i> , 2022, 36, .	0.5	0
11	HIV nucleoside reverse transcriptase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114554.	5.5	19
12	Design, antihuman immunodeficiency activity and molecular docking studies of synthesized 2-aryl and 2-pyrimidinyl pyrrolidines. <i>Molecular Diversity</i> , 2021, 25, 2045-2052.	3.9	1
13	Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 72, 1247-1250.	5.8	116
14	Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. <i>Cell</i> , 2021, 184, 460-475.e21.	28.9	156
15	COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184.	3.7	302
16	Covidâ€19 will not â€magically disappearâ€. Why access to widespread testing is paramount. <i>American Journal of Hematology</i> , 2021, 96, 174-178.	4.1	5
17	Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 31, 115952.	3.0	9
18	Moving Fast Toward Hepatitis B Virus Elimination. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 115-138.	1.6	6

#	ARTICLE	IF	CITATIONS
19	Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator. <i>Viruses</i> , 2021, 13, 114.	3.3	13
20	Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100045.	3.6	20
21	Disproportionate presence of adenosine in mitochondrial and chloroplast DNA of <i>Chlamydomonas reinhardtii</i> . <i>IScience</i> , 2021, 24, 102005.	4.1	5
22	Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase. <i>Microorganisms</i> , 2021, 9, 893.	3.6	80
23	Î ² -d ₄ -hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. <i>Journal of Infectious Diseases</i> , 2021, 224, 415-419.	4.0	211
24	Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. <i>Metabolism Open</i> , 2021, 10, 100090.	2.9	16
25	Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1555-1566.	2.0	1
26	Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. <i>Journal of Biological Chemistry</i> , 2021, 297, 100770.	3.4	200
27	Single-Amplicon Multiplex Real-Time Reverse Transcription-PCR with Tiled Probes To Detect SARS-CoV-2 <i>spike</i> Mutations Associated with Variants of Concern. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0144621.	3.9	26
28	The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency. <i>Frontiers in Immunology</i> , 2021, 12, 720697.	4.8	9
29	Structural and functional characterization explains loss of dNTPase activity of the cancer-specific R366C/H mutant SAMHD1 proteins. <i>Journal of Biological Chemistry</i> , 2021, 297, 101170.	3.4	7
30	RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2021, 2, 1-1.	2.3	6
31	Contemporary Approaches to the Discovery and Development of Broad-Spectrum Natural Product Prototypes for the Control of Coronaviruses. <i>Journal of Natural Products</i> , 2021, 84, 3001-3007.	3.0	6
32	Synthesis of 7-trifluoromethyl-7-deazapurine ribonucleoside analogs and their monophosphate prodrugs. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2020, 39, 671-687.	1.1	2
33	Disentangling the lifespans of hepatitis C virusâ€infecting cells and intracellular vRNA replicationâ€complexes during directâ€acting antiâ€viral therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 261-269.	2.0	3
34	Intracellular metabolism and potential cardiotoxicity of a Î ² -D-2â€™-C-methyl-2,6-diaminopurine ribonucleoside phosphoramidate that inhibits hepatitis C virus replication. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2020, 39, 204-224.	1.1	3
35	Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses <i>In Vitro</i> and in Humanized Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	28
36	Enhanced enzyme kinetics of reverse transcriptase variants cloned from animals infected with SIVmac239 lacking viral protein X. <i>Journal of Biological Chemistry</i> , 2020, 295, 16975-16986.	3.4	2

#	ARTICLE	IF	CITATIONS
37	Mechanistic cross-talk between DNA/RNA polymerase enzyme kinetics and nucleotide substrate availability in cells: Implications for polymerase inhibitor discovery. <i>Journal of Biological Chemistry</i> , 2020, 295, 13432-13443.	3.4	6
38	Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 6566-6578.	5.4	4
39	Repurposing Nucleoside Analogs for Human Coronaviruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	45
40	Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance. <i>Molecules</i> , 2020, 25, 4868.	3.8	3
41	Response to Correspondence: Baricitinib as Treatment of COVID-19 Friend or Foe of the Pancreas? Cerda-Contreras et.al. <i>Clinical Infectious Diseases</i> , 2020, 73, e3978-e3979.	5.8	0
42	Novel method to quantify phenotypic markers of HIV-associated neurocognitive disorder in a murine SCID model. <i>Journal of NeuroVirology</i> , 2020, 26, 838-845.	2.1	2
43	Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al. <i>Clinical Infectious Diseases</i> , 2020, 73, e3980-e3981.	5.8	1
44	Ribonucleotide incorporation in yeast genomic DNA shows preference for cytosine and guanosine preceded by deoxyadenosine. <i>Nature Communications</i> , 2020, 11, 2447.	12.8	21
45	7-Deaza-7-fluoro-2'-C-methyladenosine inhibits Zika virus infection and viral-induced neuroinflammation. <i>Antiviral Research</i> , 2020, 180, 104855.	4.1	8
46	Synthesis of 4'-Substituted-2'-Deoxy-2'-Fluoro Nucleoside Analogs as Potential Antiviral Agents. <i>Molecules</i> , 2020, 25, 1258.	3.8	5
47	Viral protein X reduces the incorporation of mutagenic noncanonical rNTPs during lentivirus reverse transcription in macrophages. <i>Journal of Biological Chemistry</i> , 2020, 295, 657-666.	3.4	3
48	Potent in vitro activity of 2'-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus. <i>Antiviral Research</i> , 2020, 175, 104712.	4.1	15
49	Ribonucleotide reductase inhibitors suppress SAMHD1 activity enhancing cytarabine efficacy. <i>EMBO Molecular Medicine</i> , 2020, 12, e10419.	6.9	35
50	SAMHD1 Functions and Human Diseases. <i>Viruses</i> , 2020, 12, 382.	3.3	51
51	Novel 2'-homo-2'-deoxy-2'-nucleosides: synthesis, characterization and biological activity. <i>RSC Advances</i> , 2020, 10, 15815-15824.	3.6	4
52	Disparate effects of Cytotoxic Chemotherapy on the Antiviral Activity of Antiretroviral Therapy: Implications for Treatments of HIV-Infected Cancer Patients. <i>Antiviral Therapy</i> , 2019, 24, 177-186.	1.0	5
53	Efficient pre-catalytic conformational change of reverse transcriptases from SAMHD1 non-counteracting primate lentiviruses during dNTP incorporation. <i>Virology</i> , 2019, 537, 36-44.	2.4	6
54	Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. <i>Protein Science</i> , 2019, 28, 1664-1675.	7.6	20

#	ARTICLE	IF	CITATIONS
55	Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	8
56	Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126639.	2.2	8
57	FRI-157-Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation. <i>Journal of Hepatology</i> , 2019, 70, e457.	3.7	3
58	Effect of induced dNTP pool imbalance on HIV-1 reverse transcription in macrophages. <i>Retrovirology</i> , 2019, 16, 29.	2.0	6
59	Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro. <i>Journal of Neuroinflammation</i> , 2019, 16, 182.	7.2	36
60	Discovery of a Series of 2-Fluoro,2-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1859-1874.	6.4	11
61	Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals. <i>International Journal of Infectious Diseases</i> , 2019, 83, 98-101.	3.3	20
62	Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis Viruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	15
63	Synthesis of 2-fluoro-substituted and 2,6-modified purine 2,3-dideoxy-2,3-difluoro-d-arabinofuranosyl nucleosides from d-xylose. <i>Tetrahedron</i> , 2019, 75, 2037-2046.	1.9	7
64	Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus. <i>Viruses</i> , 2019, 11, 1039.	3.3	14
65	Structural and Antiviral Studies of the Human Norovirus GII.4 Protease. <i>Biochemistry</i> , 2019, 58, 900-907.	2.5	11
66	Synthesis and anti-HCV activity of 2'-d-deoxy-2'-chloro-2'-fluoro and 2'-d-deoxy-2'-bromo-2'-fluoro nucleosides and their phosphoramidate prodrugs. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 664-676.	3.0	9
67	Long-term Virological and Adherence Outcomes to Antiviral Treatment in a 4-year Cohort Chronic HBV Study. <i>Antiviral Therapy</i> , 2019, 24, 567-579.	1.0	4
68	Mobile Health Intervention to Reduce HIV Transmission: A Randomized Trial of Behaviorally Enhanced HIV Treatment as Prevention (B-TasP). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 34-42.	2.1	19
69	Acute acalculous cholecystitis during zika virus infection in an immunocompromised patient. <i>Hepatology</i> , 2018, 67, 2051-2054.	7.3	6
70	Towards HBV curative therapies. <i>Liver International</i> , 2018, 38, 102-114.	3.9	63
71	Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?. <i>Liver International</i> , 2018, 38, 7-13.	3.9	128
72	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	7.3	70

#	ARTICLE	IF	CITATIONS
73	Host SAMHD1 protein restricts endogenous reverse transcription of HIV-1 in nondividing macrophages. <i>Retrovirology</i> , 2018, 15, 69.	2.0	7
74	Interplay of ancestral non-primate lentiviruses with the virus-restricting SAMHD1 proteins of their hosts. <i>Journal of Biological Chemistry</i> , 2018, 293, 16402-16412.	3.4	16
75	HIV transmission in discordant couples in Africa in the context of antiretroviral therapy availability. <i>Aids</i> , 2018, 32, 1613-1623.	2.2	5
76	Simian Immunodeficiency Virus Persistence in Cellular and Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	3.4	49
77	Template-assisted synthesis of adenine-mutagenized cDNA by a retroelement protein complex. <i>Nucleic Acids Research</i> , 2018, 46, 9711-9725.	14.5	21
78	Synthesis and antiviral evaluation of novel peptidomimetics as norovirus protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2165-2170.	2.2	14
79	Metabolism of Nucleosides and Nucleotides Prodrugs. <i>Current Pharmaceutical Design</i> , 2018, 23, 6984-7002.	1.9	8
80	Expression, Purification and Characterization of a GII.4 Norovirus Protease from Minerva Virus. <i>Infectious Disorders - Drug Targets</i> , 2018, 18, 224-232.	0.8	1
81	Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 904-910.	2.2	13
82	Characterization of 2'-deoxy-5'-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	64
83	Synthesis and antiviral evaluation of 2',3'-bis(2,3-tetrafluoro nucleoside) analogs. <i>Tetrahedron Letters</i> , 2017, 58, 642-644.	1.4	10
84	From HCV To HBV Cure. <i>Liver International</i> , 2017, 37, 73-80.	3.9	26
85	Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. <i>Antiviral Research</i> , 2017, 144, 223-246.	4.1	104
86	2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5424-5437.	6.4	23
87	Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	8
88	Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease. <i>Biochemical and Biophysical Research Communications</i> , 2017, 492, 668-673.	2.1	21
89	Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	30
90	Synthesis and anti-HCV activity of a series of 2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5296-5299.	2.2	12

#	ARTICLE	IF	CITATIONS
91	Synthesis of (2 <i>S</i>)-2-Chloro-2-fluororibolactone via Stereoselective Electrophilic Fluorination. <i>Journal of Organic Chemistry</i> , 2017, 82, 13171-13178.	3.2	7
92	A CRISPR/Cas9 approach reveals that the polymerase activity of DNA polymerase β is dispensable for HIV-1 infection in dividing and nondividing cells. <i>Journal of Biological Chemistry</i> , 2017, 292, 14016-14025.	3.4	14
93	Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 407-421.	5.5	40
94	Anti-human immunodeficiency activity of novel 2-arylpiperidine analogs. <i>Medicinal Chemistry Research</i> , 2017, 26, 101-108.	2.4	5
95	Synthesis and antiviral evaluation of fluorinated acyclo-nucleosides and their phosphoramidates. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2017, 36, 66-82.	1.1	2
96	Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice. <i>Oncotarget</i> , 2017, 8, 94040-94053.	1.8	14
97	Substrates and Inhibitors of SAMHD1. <i>PLoS ONE</i> , 2017, 12, e0169052.	2.5	45
98	Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. <i>PLoS Pathogens</i> , 2017, 13, e1006740.	4.7	71
99	Jak Inhibitors Modulate Production of Replication Competent Zika Virus in Human Hofbauer, Trophoblasts, and Neuroblastoma cells. <i>Pathogens and Immunity</i> , 2017, 2, 199.	3.1	22
100	HIV latency reversal research and the potential effects on the central nervous system: is concern warranted?. <i>Journal of the International AIDS Society</i> , 2016, 19, 21008.	3.0	0
101	Biochemical Characterization of the Active Anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4659-4669.	3.2	11
102	Zika Virus Infects Human Placental Macrophages. <i>Cell Host and Microbe</i> , 2016, 20, 83-90.	11.0	410
103	SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. <i>Virology</i> , 2016, 495, 92-100.	2.4	77
104	Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. <i>Clinics in Liver Disease</i> , 2016, 20, 737-749.	2.1	24
105	Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 97-104.	8.1	80
106	Editorial overview: Antiviral strategies. <i>Current Opinion in Virology</i> , 2016, 18, v-vi.	5.4	3
107	Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. <i>Chemical Reviews</i> , 2016, 116, 14379-14455.	47.7	265
108	Sonication-Assisted Synthesis of (E)-2-Methyl-but-2-enyl Nucleoside Phosphonate Prodrugs. <i>ChemistrySelect</i> , 2016, 1, 3108-3113.	1.5	8

#	ARTICLE	IF	CITATIONS
109	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 4101-4105.	2.2	13
110	Synthesis and Evaluation of 2,6-Modified Purine 2 <i>C</i> -Methyl Ribonucleosides as Inhibitors of HCV Replication. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 17-22.	2.8	16
111	Metabolic profiling during HIV-1 and HIV-2 infection of primary human monocyte-derived macrophages. <i>Virology</i> , 2016, 491, 106-114.	2.4	32
112	A new oxygen modification cyclooctaoxygen binds to nucleic acids as sodium crown complex. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2016, 1860, 785-794.	2.4	0
113	The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. <i>Neurobiology of Disease</i> , 2016, 92, 137-143.	4.4	60
114	Predicting Zika virus structural biology: Challenges and opportunities for intervention. <i>Antiviral Chemistry and Chemotherapy</i> , 2015, 24, 118-126.	0.6	58
115	Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis. <i>Oncotarget</i> , 2015, 6, 11047-11060.	1.8	21
116	Pre-steady state kinetic analysis of HIV-1 reverse transcriptase for non-canonical ribonucleoside triphosphate incorporation and DNA synthesis from ribonucleoside-containing DNA template. <i>Antiviral Research</i> , 2015, 115, 75-82.	4.1	4
117	Mechanistic and Kinetic Differences between Reverse Transcriptases of Vpx Coding and Non-coding Lentiviruses. <i>Journal of Biological Chemistry</i> , 2015, 290, 30078-30086.	3.4	26
118	Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. <i>Virology</i> , 2015, 476, 196-205.	2.4	202
119	Towards an HBV cure: state-of-the-art and unresolved questionsâ€”report of the ANRS workshop on HBV cure. <i>Gut</i> , 2015, 64, 1314-1326.	12.1	234
120	Synthesis of carbocyclic nucleoside analogs with five-membered heterocyclic nucleobases. <i>Tetrahedron Letters</i> , 2015, 56, 3587-3590.	1.4	7
121	Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3711-3715.	2.2	2
122	Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8596-8601.	7.1	37
123	$\hat{2}$ - <i>C</i> -Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5-Triphosphate Forms. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3445-3458.	6.4	30
124	Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors. <i>Journal of Molecular Modeling</i> , 2015, 21, 282.	1.8	5
125	Synthesis and antiviral evaluation of 2,3-dideoxy-2,3-difluoro-D-arabinofuranosyl 2,6-disubstituted purine nucleosides. <i>Heterocyclic Communications</i> , 2015, 21, 315-327.	1.2	9
126	Role of Marine Natural Products in the Genesis of Antiviral Agents. <i>Chemical Reviews</i> , 2015, 115, 9655-9706.	47.7	85

#	ARTICLE	IF	CITATIONS
127	Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4+ T cells. <i>Virology</i> , 2015, 485, 313-321.	2.4	5
128	Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. <i>Future Microbiology</i> , 2015, 10, 1773-1782.	2.0	34
129	Variation of Human Immunodeficiency Virus Type-1 Reverse Transcriptase within the Simian Immunodeficiency Virus Genome of RT-SHIV. <i>PLoS ONE</i> , 2014, 9, e86997.	2.5	2
130	Analysis of Multiply Spliced Transcripts in Lymphoid Tissue Reservoirs of Rhesus Macaques Infected with RT-SHIV during HAART. <i>PLoS ONE</i> , 2014, 9, e87914.	2.5	18
131	Residual Viremia in an RT-SHIV Rhesus Macaque HAART Model Marked by the Presence of a Predominant Plasma Clone and a Lack of Viral Evolution. <i>PLoS ONE</i> , 2014, 9, e88258.	2.5	9
132	Kinetic variations between reverse transcriptases of viral protein X coding and noncoding lentiviruses. <i>Retrovirology</i> , 2014, 11, 111.	2.0	21
133	dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages. <i>Retrovirology</i> , 2014, 11, 63.	2.0	36
134	HCV direct-acting antiviral agents: the best interferon-free combinations. <i>Liver International</i> , 2014, 34, 69-78.	3.9	213
135	Anti-HIV-1 screening of (2E)-3-(2-chloro-6-methyl/methoxyquinolin-3-yl)-1-(aryl)prop-2-en-1-ones. <i>Medicinal Chemistry Research</i> , 2014, 23, 402-407.	2.4	7
136	Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. <i>Hepatology</i> , 2014, 60, 37-45.	7.3	103
137	Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine. <i>Antiviral Research</i> , 2014, 101, 62-67.	4.1	3
138	Ruxolitinib and Tofacitinib Are Potent and Selective Inhibitors of HIV-1 Replication and Virus Reactivation <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1977-1986.	3.2	82
139	Chutes and ladders in hepatitis C nucleoside drug development. <i>Antiviral Research</i> , 2014, 102, 119-147.	4.1	69
140	Synthesis and antiviral evaluation of 2-amino-6-carbamoyl-purine dioxolane nucleoside derivatives and their phosphoramidates prodrugs. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6665-6671.	3.0	5
141	Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10031-10043.	6.4	44
142	Enhanced Antiretroviral Therapy in Rhesus Macaques Improves RT-SHIV Viral Decay Kinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3927-3933.	3.2	10
143	Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs. <i>Chemical Reviews</i> , 2014, 114, 9154-9218.	47.7	440
144	Randomized, Double-Blind, Multicenter Safety and Efficacy Study of Rifalazil Compared with Azithromycin for Treatment of Uncomplicated Genital Chlamydia trachomatis Infection in Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4014-4019.	3.2	11

#	ARTICLE	IF	CITATIONS
145	Approaches to hepatitis C treatment and cure using NS5A inhibitors. <i>Infection and Drug Resistance</i> , 2014, 7, 41.	2.7	51
146	Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6325-6330.	2.2	17
147	Treatment as prevention and cure towards global eradication of hepatitis C virus. <i>Trends in Microbiology</i> , 2013, 21, 625-633.	7.7	56
148	Synthesis of Cyclopentanyl Carbocyclic 5-Fluorocytosine (($\hat{\wedge}$)-5-Fluorocarbodine) Using a Facially Selective Hydrogenation Approach. <i>Journal of Organic Chemistry</i> , 2013, 78, 723-727.	3.2	5
149	Synthesis and evaluation of Janus type nucleosides as potential HCV NS5B polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3385-3388.	2.2	8
150	Best strategies for global HCV eradication. <i>Liver International</i> , 2013, 33, 68-79.	3.9	97
151	Synthesis and evaluation of non-dimeric HCV NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2031-2034.	2.2	21
152	Cellular Pharmacology and Potency of HIV-1 Nucleoside Analogs in Primary Human Macrophages. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1262-1269.	3.2	34
153	Prodrug strategies for improved efficacy of nucleoside antiviral inhibitors. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 556-564.	3.8	9
154	Significance of endangered and threatened plant natural products in the control of human disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16832-16837.	7.1	63
155	Preclinical Characterization of GLS4, an Inhibitor of Hepatitis B Virus Core Particle Assembly. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5344-5354.	3.2	99
156	The Impact of Macrophage Nucleotide Pools on HIV-1 Reverse Transcription, Viral Replication, and the Development of Novel Antiviral Agents. <i>Molecular Biology International</i> , 2012, 2012, 1-8.	1.7	24
157	Balancing Antiviral Potency and Host Toxicity: Identifying a Nucleotide Inhibitor with an Optimal Kinetic Phenotype for HIV-1 Reverse Transcriptase. <i>Molecular Pharmacology</i> , 2012, 82, 125-133.	2.3	16
158	Antiviral Activity of Nucleoside Analogues against Norovirus. <i>Antiviral Therapy</i> , 2012, 17, 981-991.	1.0	63
159	Antiretroviral Monocyte Efficacy Score Linked to Cognitive Impairment in Hiv. <i>Antiviral Therapy</i> , 2012, 17, 1233-1242.	1.0	66
160	Evaluation of Single and Combination Therapies with Tenofovir Disoproxil Fumarate and Emtricitabine <i>In Vitro</i> and in a Robust Mouse Model Supporting High Levels of Hepatitis B Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 6186-6191.	3.2	11
161	Practical considerations for developing nucleoside reverse transcriptase inhibitors. <i>Drug Discovery Today: Technologies</i> , 2012, 9, e183-e193.	4.0	15
162	Anti-HIV-1 and cytotoxicity studies of piperidyl-thienyl chalcones and their 2-pyrazoline derivatives. <i>Medicinal Chemistry Research</i> , 2012, 21, 3741-3749.	2.4	57

#	ARTICLE	IF	CITATIONS
163	Scaleable processes for the synthesis of (âˆ™)-Î²-d-2,6-diaminopurine dioxolane (Amdoxovir, DAPD) and (âˆ™)-Î²-d-2-aminopurine dioxolane (APD). <i>Tetrahedron</i> , 2012, 68, 5738-5743.	1.9	6
164	Synthesis and evaluation of novel potent HCV NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4864-4868.	2.2	13
165	Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3488-3491.	2.2	22
166	Simian immunodeficiency virus macaque models of HIV latency. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 57-61.	3.8	23
167	Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3â€²-azido-2â€²,3â€²-dideoxypurine nucleosides. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 3832-3844.	5.5	12
168	In silico study supports the efficacy of a reduced dose regimen for stavudine. <i>Antiviral Research</i> , 2011, 92, 372-377.	4.1	6
169	Synthesis of purine modified 2â€²-C-methyl nucleosides as potential anti-HCV agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6788-6792.	2.2	13
170	Synthesis and antiviral activity of 2â€²-deoxy-2â€²-fluoro-2â€²-C-methyl-7-deazapurine nucleosides, their phosphoramidate prodrugs and 5â€²-triphosphates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 7094-7098.	2.2	19
171	Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection. <i>Tetrahedron</i> , 2011, 67, 5487-5493.	1.9	20
172	Synthesis and Biological Evaluation of 4â€²-â€‹C</i>,3â€²-â€‹O</i>-â€‹Propyleneâ€‹Linked Bicyclic Nucleosides. <i>European Journal of Organic Chemistry</i> , 2011, 2011, 7390-7399.	2.4	7
173	The Base Component of 3â€²-Azido-2â€²,3â€²-Dideoxynucleosides Influences Resistance Mutations Selected in HIV-1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3758-3764.	3.2	1
174	Selection and Characterization of HIV-1 with a Novel S68 Deletion in Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2054-2060.	3.2	7
175	Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals. <i>Antiviral Therapy</i> , 2010, 15, 185-192.	1.0	13
176	Advances in nucleoside monophosphate prodrugs as anti-HCV agents. <i>Antiviral Therapy</i> , 2010, 15, 935-950.	1.0	51
177	Synthesis of 6-imino-5-tetrahydro-1H-2-pyrrolylidenhexahydro-2,4-pyrimidinediones as intermediates for the synthesis of C-azanucleosides. <i>Tetrahedron Letters</i> , 2010, 51, 231-233.	1.4	9
178	Synthesis and evaluation of 3â€²-azido-2â€²,3â€²-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 60-64.	2.2	13
179	Lack of Pharmacokinetic Interaction between Amdoxovir and Reduced- and Standard-Dose Zidovudine in HIV-1-Infected Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1248-1255.	3.2	7
180	Ribonucleoside Triphosphates as Substrate of Human Immunodeficiency Virus Type 1 Reverse Transcriptase in Human Macrophages. <i>Journal of Biological Chemistry</i> , 2010, 285, 39380-39391.	3.4	94

#	ARTICLE	IF	CITATIONS
181	Viral Sanctuaries during Highly Active Antiretroviral Therapy in a Nonhuman Primate Model for AIDS. <i>Journal of Virology</i> , 2010, 84, 2913-2922.	3.4	163
182	Simultaneous Quantification of Intracellular Natural and Antiretroviral Nucleosides and Nucleotides by Liquid Chromatography-Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2010, 82, 1982-1989.	6.5	44
183	Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome. <i>PLoS ONE</i> , 2010, 5, e9948.	2.5	46
184	Viral Decay Kinetics in the Highly Active Antiretroviral Therapy-Treated Rhesus Macaque Model of AIDS. <i>PLoS ONE</i> , 2010, 5, e11640.	2.5	13
185	Antiretroviral Therapy in Macrophages: Implication for HIV Eradication. <i>Antiviral Chemistry and Chemotherapy</i> , 2009, 20, 63-78.	0.6	86
186	Anti-Human Immunodeficiency Virus Activity, Cross-Resistance, Cytotoxicity, and Intracellular Pharmacology of the 3'-Azido-2,3'-Dideoxypurine Nucleosides. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3715-3719.	3.2	19
187	Anti-hepatitis C Virus Activity of Novel 2'-Deoxy-5-methyl-4-azido Pyrimidine Nucleoside Phosphoramidate Prodrugs. <i>Antiviral Chemistry and Chemotherapy</i> , 2009, 20, 99-106.	0.6	25
188	Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V. <i>Antiviral Research</i> , 2009, 83, 317-323.	4.1	13
189	Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3845-3851.	5.5	11
190	Cu(I)-Catalyzed Huisgen Azide-Alkyne 1,3-Dipolar Cycloaddition Reaction in Nucleoside, Nucleotide, and Oligonucleotide Chemistry. <i>Chemical Reviews</i> , 2009, 109, 4207-4220.	47.7	732
191	Approaches for the Development of Antiviral Compounds: The Case of Hepatitis C Virus. <i>Handbook of Experimental Pharmacology</i> , 2009, , 25-51.	1.8	9
192	Synthesis and anti-HIV activity of 5-haloethynyl and 5-(1,2-dihalo)vinyl analogues of AZT and FLT. <i>Tetrahedron</i> , 2008, 64, 4444-4452.	1.9	9
193	Preparation of ribavirin analogues by copper- and ruthenium-catalyzed azide-alkyne 1,3-dipolar cycloaddition. <i>Tetrahedron</i> , 2008, 64, 9044-9051.	1.9	78
194	Acyclovir Is Activated into a HIV-1 Reverse Transcriptase Inhibitor in Herpesvirus-Infected Human Tissues. <i>Cell Host and Microbe</i> , 2008, 4, 260-270.	11.0	119
195	Combinations of 2'-Methylcytidine Analogues with Interferon- β and Triple Combination with Ribavirin in the Hepatitis C Virus Replicon System. <i>Antiviral Chemistry and Chemotherapy</i> , 2008, 19, 25-31.	0.6	30
196	Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4241-4250.	3.2	17
197	Mechanism of Activation of 2'-Deoxy-2-Fluoro-5-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 503-509.	3.2	101
198	Development of a Novel Mouse Model to Evaluate Drug Candidates against Hepatitis B Virus. <i>Antiviral Chemistry and Chemotherapy</i> , 2007, 18, 213-223.	0.6	10

#	ARTICLE	IF	CITATIONS
199	Antiviral and Cellular Metabolism Interactions between Dextrovalacycline and Lamivudine. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2130-2135.	3.2	11
200	Biochemical Studies on the Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to 1-(β -D-Dioxolane)Thymine Triphosphate. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2078-2084.	3.2	13
201	Development of a Population Simulation Model for HIV Monotherapy Virological Outcomes Using Lamivudine. <i>Antiviral Chemistry and Chemotherapy</i> , 2007, 18, 329-341.	0.6	10
202	Pharmacokinetics of the Antiviral Agent β -D-2-Deoxy-2-Fluoro-2-C-Methylcytidine in Rhesus Monkeys. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2877-2882.	3.2	10
203	Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4428-4431.	2.2	63
204	Synthesis and anti-HIV activity of (β -D)- β -D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (β -D)- β -D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs. <i>Antiviral Research</i> , 2007, 75, 198-209.	4.1	16
205	Facile Purification of Honokiol and Its Antiviral and Cytotoxic Properties. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3426-3427.	6.4	51
206	Synthesis and antiviral activity of 2-deoxy-2-fluoro-2-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 1712-1715.	2.2	56
207	Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. <i>Antiviral Research</i> , 2006, 71, 322-334.	4.1	51
208	Inhibition of Hepatitis C Replicon RNA Synthesis by β -D-2-Deoxy-2-Fluoro-2-C-Methylcytidine: A Specific Inhibitor of Hepatitis C Virus Replication. <i>Antiviral Chemistry and Chemotherapy</i> , 2006, 17, 79-87.	0.6	110
209	In Vitro Activity of Structurally Diverse Nucleoside Analogs against Human Immunodeficiency Virus Type 1 with the K65R Mutation in Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1139-1144.	3.2	60
210	In Vitro Selection and Analysis of Human Immunodeficiency Virus Type 1 Resistant to Derivatives of β -D-2,3-Didehydro-2,3-Dideoxy-5-Fluorocytidine. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3930-3932.	3.2	16
211	Comparative Pharmacokinetics of Racivir [®] , (β -D)- β -D-2,3-Dideoxy-5-Fluoro-3-Thiacytidine in Rats, Rabbits, Dogs, Monkeys and HIV-Infected Humans. <i>Antiviral Chemistry and Chemotherapy</i> , 2005, 16, 117-127.	0.6	17
212	Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2618-2624.	3.2	11
213	The 3-Azido Group Is Not the Primary Determinant of 3-Azido-3-deoxythymidine (AZT) Responsible for the Excision Phenotype of AZT-resistant HIV-1. <i>Journal of Biological Chemistry</i> , 2005, 280, 29047-29052.	3.4	38
214	Suppression of Virus Load by Highly Active Antiretroviral Therapy in Rhesus Macaques Infected with a Recombinant Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2005, 79, 7349-7354.	3.4	61
215	N 4-Hydroxycytosine Dioxolane Nucleosides and Their Activity Against Hepatitis B Virus. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2005, 24, 1209-1214.	1.1	2
216	Pharmacology and Pharmacokinetics of the Antiviral Agent β -D-2,3-Dideoxy-3-Oxa-5-Fluorocytidine in Cells and Rhesus Monkeys. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2589-2597.	3.2	7

#	ARTICLE	IF	CITATIONS
217	The Boron-10 Neutron Capture Agent $^{12}\text{-d-5-o-Carboranyl-2\text{-deoxyuridine}}$ Accumulates Preferentially in Dividing Brain Tumor Cells. <i>Journal of Neuro-Oncology</i> , 2005, 74, 275-280.	2.9	7
218	Anti-HIV Activity of $(\text{2R,4R})\text{-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)-thymine}$ against Drug-Resistant HIV-1 Mutants and Studies of Its Molecular Mechanism. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3949-3952.	6.4	23
219	ESR as a valuable tool for the investigation of the dynamics of EPC and EPC/cholesterol liposomes containing a carboranyl-nucleoside intended for BNCT. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2005, 1712, 81-91.	2.6	13
220	Synthesis, Antiviral Activity, and Mechanism of Drug Resistance of $\text{d- and l-2,3-Didehydro-2,3-dideoxy-2-fluorocarboxylic Nucleosides}$. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3736-3748.	6.4	32
221	Design, Synthesis, and Antiviral Activity of $2\text{-Deoxy-2-fluoro-2-C-methylcytidine}$, a Potent Inhibitor of Hepatitis C Virus Replication. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5504-5508.	6.4	189
222	Synthesis of $\text{Enantiomers of 4-Hydroxy-3-Deoxy-Pyrimidine Nucleosides}$ and Their Evaluation against Bovine Viral Diarrhoea Virus and Hepatitis C Virus in Cell Culture. <i>Antiviral Chemistry and Chemotherapy</i> , 2004, 15, 43-55.	0.6	15
223	Relationship between Antiviral Activity and Host Toxicity: Comparison of the Incorporation Efficiencies of $2,3\text{-Dideoxy-5-Fluoro-3-Thiacytidine-Triphosphate}$ Analogs by Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Human Mitochondrial DNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1300-1306.	3.2	71
224	Metabolism of the Anti-Hepatitis C Virus Nucleoside $\text{d- N 4 -Hydroxycytidine}$ in Different Liver Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4636-4642.	3.2	30
225	Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 895-919.	2.1	71
226	Efavirenz Therapy in Rhesus Macaques Infected with a Chimera of Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3483-3490.	3.2	40
227	Investigating the effects of stereochemistry on incorporation and removal of 5-fluorocytidine analogs by mitochondrial DNA polymerase gamma: comparison of d- and l-D4FC-TP. <i>Antiviral Research</i> , 2004, 62, 57-64.	4.1	14
228	$2,3\text{-Didehydro-2,3-dideoxynucleosides}$ are degraded to furfuryl alcohol under acidic conditions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2159-2162.	2.2	7
229	Synthesis, Structure-Activity Relationships, and Drug Resistance of $\text{d-3-Fluoro-2,3-Unsaturated Nucleosides}$ as Anti-HIV Agents. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 3399-3408.	6.4	57
230	Tissue Disposition of Carboranyluracil : A Novel Agent for the Boron Neutron Capture Therapy of Prostate Cancer. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 291-306.	1.1	18
231	Cofactor Mimics as Selective Inhibitors of NAD-dependent Inosine Monophosphate Dehydrogenase (IMPDH) - the Major Therapeutic Target. <i>Current Medicinal Chemistry</i> , 2004, 11, 887-900.	2.4	60
232	Potent antiviral effect of reveset in HIV-1-infected adults following a single oral dose. <i>Antiviral Therapy</i> , 2004, 9, 529-36.	1.0	5
233	Potent Antiviral Effect of Reveset in HIV-1-Infected Adults following a Single Oral Dose. <i>Antiviral Therapy</i> , 2004, 9, 529-536.	1.0	11
234	Emtricitabine. <i>Drugs</i> , 2003, 63, 2425-2426.	10.9	3

#	ARTICLE	IF	CITATIONS
235	l-2',3'-Dideoxy-2',3'-dideoxy-3'-fluoronucleosides: Synthesis, Anti-HIV Activity, Chemical and Enzymatic Stability, and Mechanism of Resistance. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3245-3256.	6.4	46
236	Probing the Mechanistic Consequences of 5-Fluorine Substitution on Cytidine Nucleotide Analogue Incorporation by HIV-1 Reverse Transcriptase. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 115-125.	0.6	22
237	4-Acyl-Modified D-2',3'-Dideoxy-5-Fluorocytidine Nucleoside Analogues with Improved Antiviral Activity. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 81-90.	0.6	3
238	Cellular Pharmacology of D-d4FC, a Nucleoside Analogue Active against Drug-Resistant HIV. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 39-47.	0.6	15
239	Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 244-254.	3.2	175
240	HIV-1 Resistance Profile of the Novel Nucleoside Reverse Transcriptase Inhibitor Î²-D-2',3'-Dideoxy-2',3'-Dideoxy-5-Fluorocytidine (Reversetâ„¸). <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 49-59.	0.6	34
241	Dynamics of Subgenomic Hepatitis C Virus Replicon RNA Levels in Huh-7 Cells after Exposure to Nucleoside Antimetabolites. <i>Journal of Virology</i> , 2003, 77, 10689-10694.	3.4	70
242	Preclinical and clinical development of the anti-HIV, anti-HBV oxathiolane nucleoside analog emtricitabine. , 2003, , 451-484.		4
243	CD81 receptor expression in human cells. , 2003, , 485-492.		0
244	Viral Pharmacodynamic Model for (â„¸)-Î²-2',3'-Dideoxy-5-Fluoro-3'-Thiacytidine (Emtricitabine) in Chronically Infected Woodchucks. <i>Antiviral Chemistry and Chemotherapy</i> , 2002, 13, 165-176.	0.6	2
245	Review Hepatitis B Virus Resistance to Lamivudine and its Clinical Implications. <i>Antiviral Chemistry and Chemotherapy</i> , 2002, 13, 143-155.	0.6	11
246	Antiviral Activities and Cellular Toxicities of Modified 2',3'-Dideoxy-2',3'-Dideoxy-5-Fluorocytidine Analogues. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3854-3860.	3.2	120
247	DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1394-1401.	3.2	48
248	Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. <i>Antiviral Research</i> , 2002, 55, 141-150.	4.1	23
249	Interactions of enantiomers of 2',3'-dideoxy-2',3'-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. <i>Antiviral Research</i> , 2002, 56, 189-205.	4.1	24
250	Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. <i>Antiviral Research</i> , 2002, 56, 115-127.	4.1	14
251	Synthesis and Potent Anti-HIV Activity of 3'-Fluoro-2',3'-Unsaturated Cytidine. <i>Organic Letters</i> , 2001, 3, 4177-4180.	4.6	28
252	Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. <i>Hepatology</i> , 2001, 33, 751-757.	7.3	351

#	ARTICLE	IF	CITATIONS
253	Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 229-235.	3.2	179
254	ANTI-HBV SPECIFIC 1- β -D-DEOXYNUCLEOSIDES. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2001, 20, 597-607.	1.1	22
255	Mechanism of Action of 1- β -d-2,6-Diaminopurine Dioxolane, a Prodrug of the Human Immunodeficiency Virus Type 1 Inhibitor 1- β -d-Dioxolane Guanosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 158-165.	3.2	81
256	The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. <i>Journal of Clinical Investigation</i> , 2001, 107, 449-455.	8.2	255
257	Synthesis of 2,3-dideoxy-3-fluoro-l-ribonucleosides as potential antiviral agents from d-sorbitol. <i>Carbohydrate Research</i> , 2000, 328, 49-59.	2.3	24
258	Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2,3,5-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 235-240.	2.3	6
259	Differential Removal of Thymidine Nucleotide Analogues from Blocked DNA Chains by Human Immunodeficiency Virus Reverse Transcriptase in the Presence of Physiological Concentrations of 2-Deoxynucleoside Triphosphates. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 3465-3472.	3.2	108
260	Human Herpesvirus 8 Open Reading Frame 21 Is a Thymidine and Thymidylate Kinase of Narrow Substrate Specificity That Efficiently Phosphorylates Zidovudine but Not Ganciclovir. <i>Journal of Virology</i> , 2000, 74, 684-692.	3.4	77
261	In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (β)-1- β -d-Dioxolane-Guanosine and Suppress Resistance to 3-Azido-3-Deoxythymidine. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1783-1788.	3.2	95
262	Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 351-361.	2.3	14
263	Cellular Pharmacology of the D- and L-Enantiomers of 1-5-o-Carboranyl-2-deoxyuridine. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2000, 19, 691-702.	1.1	13
264	Synthesis and Antiviral Activities of Enantiomeric 1-[2-(Hydroxymethyl) Cyclopropyl] Methyl Nucleosides. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2000, 19, 253-268.	1.1	8
265	Enhanced Antiviral Benefit of Combination Therapy with Lamivudine and Alpha Interferon against WHV Replication in Chronic Carrier Woodchucks. <i>Antiviral Therapy</i> , 2000, 5, 95-104.	1.0	43
266	Mechanistic studies show that (β)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. <i>FASEB Journal</i> , 1999, 13, 1511-1517.	0.5	66
267	A New Point Mutation (P157S) in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Confers Low-Level Resistance to (β)-1- β -2,3-Dideoxy-3-Thiacytidine. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2077-2080.	3.2	12
268	Pharmacokinetics of (-)-beta-D-Dioxolane Guanine and Prodrug (-)-beta-D-2,6-Diaminopurine Dioxolane in Rats and Monkeys. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1625-1630.	1.1	21
269	Cell-Based and Animal Models for Hepatitis B and C Viruses. <i>Antiviral Chemistry and Chemotherapy</i> , 1999, 10, 99-114.	0.6	34
270	Enantioselective synthesis and biological evaluation of 5-o-carboranyl pyrimidine nucleosides. <i>Bioorganic and Medicinal Chemistry</i> , 1999, 7, 2759-2766.	3.0	12

#	ARTICLE	IF	CITATIONS
271	Nucleic acids and nucleosides containing carboranes. <i>Journal of Organometallic Chemistry</i> , 1999, 581, 156-169.	1.8	84
272	New Classes of Fluorinated L-Nucleosides; Synthesis and Antiviral Activity. <i>Nucleosides & Nucleotides</i> , 1999, 18, 537-540.	0.5	23
273	Synthesis and Biological Evaluation of 2',3'-Didehydro-2',3'-dideoxy-5- fluorocytidine (D4FC) Analogues:Â Discovery of Carbocyclic Nucleoside Triphosphates with Potent Inhibitory Activity against HIV-1 Reverse Transcriptase1. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 859-867.	6.4	51
274	Synthesis and Anti-HIV and Anti-HBV Activities of 2'-Fluoro-2',3'-unsaturated l-Nucleosides. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1320-1328.	6.4	71
275	From d-to l-nucleoside analogs as antiviral agents. <i>Advances in Antiviral Drug Design</i> , 1999, , 1-68.	0.6	21
276	Pharmacokinetics of the Antiviral Agent Î²- d -2',3'-Didehydro-2',3'-Dideoxy-5-Fluorocytidine in Rhesus Monkeys. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 381-384.	3.2	14
277	Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy. <i>Antiviral Therapy</i> , 1999, 4, 21-28.	1.0	30
278	Synthesis and Biological Properties of the Four Optical Isomers of 5-o-Carboranyl-2',3'-didehydro-2',3'-dideoxyuridine. <i>Nucleosides & Nucleotides</i> , 1998, 17, 711-727.	0.5	9
279	Pharmacodynamics of (âˆ™)-Î²-2',3'-Dideoxy-3'-Thiacytidine in Chronically Virus-Infected Woodchucks Compared to Its Pharmacodynamics in Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2804-2809.	3.2	19
280	Synthesis, Biological Activity and Decomposition Studies of Amino Acid Phosphomonoester Amidates of Acyclovir. <i>Nucleosides & Nucleotides</i> , 1997, 16, 2079-2092.	0.5	13
281	A General Synthetic Method of 5-Carboranyluracil Nucleosides with Potential Antiviral Activity and use in Neutron Capture Therapy. <i>Nucleosides & Nucleotides</i> , 1997, 16, 2133-2150.	0.5	12
282	Structureâˆ³Activity Relationships of 2'-Deoxy-2',2'-difluoro-l-erythro-pentofuranosyl Nucleosides. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3635-3644.	6.4	50
283	Comparison of Physicochemical and Biological Properties of (<i>o</i>-Carboran-1-yl)methylphosphonate and Methylphosphonate Oligonucleotides. <i>Nucleosides & Nucleotides</i> , 1997, 16, 1503-1505.	0.5	8
284	Synthesis of Six-Membered Nucleoside Analogs. Part 1: Pyrimidine Nucleosides Based on the 1,3-Dioxane Ring System. <i>Nucleosides & Nucleotides</i> , 1997, 16, 403-416.	0.5	8
285	Biotransformation and pharmacokinetics of prodrug 9-(Î²-d-1,3-dioxolan-4-yl)-2-aminopurine and its antiviral metabolite 9-(Î²-d-1,3-dioxolan-4-yl)guanine in mice. <i>Antiviral Research</i> , 1997, 35, 187-193.	4.1	9
286	Synthesis, Biotransformation, and Pharmacokinetic Studies of 9-(Î²-d-Arabinofuranosyl)-6-azidopurine:Â A Prodrug for Ara-A Designed To Utilize the Azide Reduction Pathway1. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 5202-5207.	6.4	38
287	Effect of Î²-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. <i>Biochemical Pharmacology</i> , 1996, 52, 1577-1584.	4.4	54
288	Cloning and Expression of Sporozoite and Oocyst <i>Cryptosporidium parvum</i> Recombinant Proteins.. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 83S-83S.	1.7	3

#	ARTICLE	IF	CITATIONS
289	In Vitro Evaluation of Anticryptosporidial Agents Using MDCK Cell Culture and Chemiluminescence Immunoassay. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 87S-87S.	1.7	8
290	A chemiluminescence immunoassay for evaluation of <i>Cryptosporidium parvum</i> growth in vitro. <i>FEMS Microbiology Letters</i> , 1996, 136, 251-256.	1.8	29
291	In Vitro Expression of mRNA Coding For a <i>Cryptosporidium parvum</i> Oocyst Wall Protein. <i>Journal of Eukaryotic Microbiology</i> , 1996, 43, 84s-85S.	1.7	6
292	Anti-human immunodeficiency virus type-1 (HIV-1) and anti-hepatitis B virus (HBV) activities of (2,3-dideoxy-2-fluoro-1 ² -L-threo-pentofuranosyl)nucleosides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1995, 5, 877-880.	2.2	16
293	Boron Containing Pyrimidines, Nucleosides, and Oligonucleotides for Neutron Capture Therapy. <i>Nucleosides & Nucleotides</i> , 1994, 13, 849-880.	0.5	58
294	Pharmacokinetics of 5- ^o -Carboranyl-2 ^{â€²} -deoxyuridine in Rats. <i>Journal of Pharmaceutical Sciences</i> , 1994, 83, 1697-1699.	3.3	13
295	Cellular pharmacology and biological activity of 5-carboranyl-2 ^{â€²} -deoxyuridine. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 28, 1113-1120.	0.8	45
296	Carboranyl Oligonucleotides for Antisense Technology and Boron Neutron Capture Therapy of Cancers. <i>ACS Symposium Series</i> , 1994, , 169-182.	0.5	11
297	Multiple drug effect analysis with confidence interval. <i>Antiviral Research</i> , 1994, 25, 1-11.	4.1	79
298	Carboranyl Oligonucleotides. 2. Synthesis and Physicochemical Properties of Dodecathymidylate Containing 5-(^o -Carboranyl-1-yl)-2'-deoxyuridine. <i>Journal of the American Chemical Society</i> , 1994, 116, 7494-7501.	13.7	45
299	Synthesis and Biological Properties of 5- ^o -Carboranyl-1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)uracil. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 2583-2588.	6.4	18
300	Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activity of pyrimidine oxathiolane nucleosides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 693-696.	2.2	13
301	The synthesis and anti-hiv activity of pyrimidine dioxolanyl nucleosides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1993, 3, 169-174.	2.2	24
302	1,3-Dioxolanyl-purine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 30-37.	6.4	90
303	Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2 ^{â€²} -deoxycytidine kinase. <i>Biochemical Pharmacology</i> , 1993, 45, 1540-1543.	4.4	93
304	L. β -(2S,4S)- and L. α -(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 519-528.	6.4	89
305	Derivatives of 4 ^{â€²} -amino-6 ^{â€²} -disulfonato-1, 8 ^{â€²} -naphthalimide inhibit reverse transcriptase and suppress human and feline immunodeficiency virus expression in cultured cells. <i>Journal of Cellular Biochemistry</i> , 1993, 51, 446-457.	2.6	28
306	A Short Synthesis of 2 ^{â€²} ,3 ^{â€²} -Didehydro-3 ^{â€²} -deoxythymidine. <i>Nucleosides & Nucleotides</i> , 1993, 12, 149-155.	0.5	12

#	ARTICLE	IF	CITATIONS
307	Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy. <i>FASEB Journal</i> , 1993, 7, 1070-1080.	0.5	17
308	Enzyme-mediated enantioselective preparation of pure enantiomers of the antiviral agent 2',3'-dideoxy-5-fluoro-3'-thiacytidine (FTC) and related compounds. <i>Journal of Organic Chemistry</i> , 1992, 57, 5563-5565.	3.2	91
309	Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity.. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 1987-1995.	6.4	112
310	Synthesis of enantiomerically pure (2'R,5'S)-(-)-1-(2-hydroxymethylthiolan-5-yl)cytosine as a potent antiviral agent against hepatitis B virus (HBV) and human immunodeficiency virus (HIV). <i>Journal of Organic Chemistry</i> , 1992, 57, 2217-2219.	3.2	207
311	In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of thialanyl and dioxolanyl nucleoside analogs. <i>Journal of the American Chemical Society</i> , 1991, 113, 9377-9379.	13.7	134
312	Asymmetric synthesis of enantiomerically pure (âˆ™)-(1â€²R,4â€²R)-dioxolane-thymine and its anti-HIV activity.. <i>Tetrahedron Letters</i> , 1991, 32, 3791-3794.	1.4	55
313	Comparative pharmacokinetics and interspecies scaling of 3'-azido-3'-deoxythymidine (AZT) in several mammalian species.. <i>Journal of Pharmacobio-dynamics</i> , 1990, 13, 206-211.	0.5	40
314	3â€²-Azido-2â€²,3â€²-Dideoxyuridine (AzddU): Comparative Pharmacokinetics with 3â€²-Azido-3â€²-Deoxythymidine (AZT) in Monkeys. <i>AIDS Research and Human Retroviruses</i> , 1990, 6, 219-228.	1.1	43
315	Nucleosides. 136. Synthesis and antiviral effects of several 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-alkyluracils. Some structure-activity relationships. <i>Journal of Medicinal Chemistry</i> , 1986, 29, 151-154.	6.4	42
316	Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents. <i>Journal of Medicinal Chemistry</i> , 1985, 28, 741-748.	6.4	53
317	Combined Antiviral Effect of Interferon and Acyclovir on Herpes Simplex Virus Types 1 and 2. <i>Antimicrobial Agents and Chemotherapy</i> , 1981, 19, 672-674.	3.2	55
318	Antiviral iodinated pyrimidine deoxyribonucleosides: 5-iodo-2â€²-deoxyuridine; 5â€²-iodo-2â€²-deoxycytidine; 5-iodo-5â€²-amino-2â€²,5â€²-dideoxyuridine. , 1979, 7, 1-34.		37
319	Antiviral and antineoplastic activities of pyrimidine arabinosyl nucleosides and their 5'-amino derivatives. <i>Journal of Medicinal Chemistry</i> , 1979, 22, 1273-1277.	6.4	29